Secondary hormonal therapy for prostate cancer: What lies on the horizon?

Nima Sharifi, William L. Dahut, William D. Figg

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Androgen deprivation therapy with medical or surgical castration is generally the first-line treatment against advanced prostate cancer. Almost invariably, metastatic prostate cancer overcomes testosterone depletion and grows, despite castrate levels of testosterone. Despite advances in cytotoxic chemotherapy, secondary hormonal therapies are often used after the development of castrate-resistant prostate cancer. Secondary hormonal therapies either lower the androgen levels further or directly antagonize the androgen receptor in prostate cancer cells. We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor.

Original languageEnglish (US)
Pages (from-to)271-274
Number of pages4
JournalBJU International
Volume101
Issue number3
DOIs
StatePublished - Feb 2008

Fingerprint

Prostatic Neoplasms
Androgens
Androgen Receptors
Testosterone
Castration
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Urology

Cite this

Secondary hormonal therapy for prostate cancer : What lies on the horizon? / Sharifi, Nima; Dahut, William L.; Figg, William D.

In: BJU International, Vol. 101, No. 3, 02.2008, p. 271-274.

Research output: Contribution to journalArticle

Sharifi, Nima ; Dahut, William L. ; Figg, William D. / Secondary hormonal therapy for prostate cancer : What lies on the horizon?. In: BJU International. 2008 ; Vol. 101, No. 3. pp. 271-274.
@article{00defd4e1bfb448daf236b156b9f16bb,
title = "Secondary hormonal therapy for prostate cancer: What lies on the horizon?",
abstract = "Androgen deprivation therapy with medical or surgical castration is generally the first-line treatment against advanced prostate cancer. Almost invariably, metastatic prostate cancer overcomes testosterone depletion and grows, despite castrate levels of testosterone. Despite advances in cytotoxic chemotherapy, secondary hormonal therapies are often used after the development of castrate-resistant prostate cancer. Secondary hormonal therapies either lower the androgen levels further or directly antagonize the androgen receptor in prostate cancer cells. We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor.",
author = "Nima Sharifi and Dahut, {William L.} and Figg, {William D.}",
year = "2008",
month = "2",
doi = "10.1111/j.1464-410X.2007.07236.x",
language = "English (US)",
volume = "101",
pages = "271--274",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Secondary hormonal therapy for prostate cancer

T2 - What lies on the horizon?

AU - Sharifi, Nima

AU - Dahut, William L.

AU - Figg, William D.

PY - 2008/2

Y1 - 2008/2

N2 - Androgen deprivation therapy with medical or surgical castration is generally the first-line treatment against advanced prostate cancer. Almost invariably, metastatic prostate cancer overcomes testosterone depletion and grows, despite castrate levels of testosterone. Despite advances in cytotoxic chemotherapy, secondary hormonal therapies are often used after the development of castrate-resistant prostate cancer. Secondary hormonal therapies either lower the androgen levels further or directly antagonize the androgen receptor in prostate cancer cells. We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor.

AB - Androgen deprivation therapy with medical or surgical castration is generally the first-line treatment against advanced prostate cancer. Almost invariably, metastatic prostate cancer overcomes testosterone depletion and grows, despite castrate levels of testosterone. Despite advances in cytotoxic chemotherapy, secondary hormonal therapies are often used after the development of castrate-resistant prostate cancer. Secondary hormonal therapies either lower the androgen levels further or directly antagonize the androgen receptor in prostate cancer cells. We discuss novel secondary hormonal agents that are under development, which work by either inhibiting androgen synthesis or directly targeting the androgen receptor.

UR - http://www.scopus.com/inward/record.url?scp=37849000456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849000456&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2007.07236.x

DO - 10.1111/j.1464-410X.2007.07236.x

M3 - Article

C2 - 17922868

AN - SCOPUS:37849000456

VL - 101

SP - 271

EP - 274

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -